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DEVELOPMENT OF COST-EFFECTIVE
WEB-BASED OUTCOMES RESEARCH STUDIES 
AND DISEASE MANAGEMENT PROGRAMS
Ambegaonkar AJ, Day D
Pfizer, Inc, Alexandria, VA, USA
Innovations in information technology are rapidly chang-
ing the health care market. With more and more clinical
trials being conducted and managed on the web, the In-
ternet provides an opportunity for conducting effective
multi-center outcomes research studies and developing
disease management programs. OBJECTIVES: This re-
search describes the development of a web-driven appli-
cation for ongoing collection, analysis, and reporting of
outcomes research data. In addition, the web application
was developed to gain experience in provision of bench-
marking reports to health care providers conducting dis-
ease management programs. METHODS: Given current
privacy regulations a multi-level security system with er-
ror checking was developed to assure integrity of data en-
tering the system. Through integration of several pro-
gramming languages (Visual Basic Script, Java Script, and
HTML) into web-based active server pages, a method for
immediate data collection, summary, and on-demand re-
porting was successfully developed. The system was de-
ployed remotely via an Internet Service Provider. A pro-
spective multi-site (10) hospital based infectious disease
study of fungal risk and treatment patterns; and a retro-
spective lipid/cardiology clinic based study of patient care
was conducted using the above technology. RESULTS:
For expenditures of less than $1,000, secure web applica-
tions were developed that provided electronic data cap-
ture of all study variables. The customizability of the pro-
gram allowed for developing applications for differing
disease states thereby reducing set-up costs and improving
efficiency. Simultaneous multi-site training and minimal
data entry errors further reduced costs. The applications
also provided real-time reports that enhanced patient-
care and reported practice patterns that highlighted na-
tional and regional variations. CONCLUSIONS: The
success of these studies has demonstrated the utility of
the internet in providing health care practitioners with a
cost-effective tool for efficiently conducting multi-center
outcomes research and disease management. Considering
the increasing popularity and access to the Internet, this
research has significant implications for outcomes re-
search and disease management.
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DOES WHERE YOU LIVE AFFECT IF AND HOW 
YOU DISCOUNT FUTURE COSTS AND 
BENEFITS IN ECONOMIC EVALUATION? 
SHOULD IT?
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University, Hamilton, ON, Canada
OBJECTIVES: An accepted practice with unresolved is-
sues in economic evaluation is the discounting of future
costs and benefits. Many people conducting evaluations
view discounting as a technical matter and look to guide-
lines for the proper rate. Therefore, we ask three ques-
tions about international guidelines: 1) what discount
rate(s) are recommended; 2) do they differ for costs and
health outcomes; 3) what is the underlying theory for dis-
counting and rationale for the rate(s)? METHODS: We
review recommendations about discounting in interna-
tional guidelines according to underlying theory used to
recommend discounting, suggested rates, rationale for
particular rates, whether a different rate was suggested
for health outcomes, and what literature was cited. RE-
SULTS/CONCLUSION: Australia, Canada, and Ontario
recommend discounting costs and health outcomes at
5%, the US 3%, New Zealand 10%, and the Netherlands
4%, while the UK recommends 6% for costs and 1.5%
for health outcomes. Most countries recognize the con-
troversy, yet remain unconvinced that health outcomes
should be discounted at different rates. While the pri-
mary stated underlying theory for discounting is time
preference, the rationale (if provided) for the particular
rates recommended varies across countries. Most often, it
relies on empirical estimates of government bond rates
and/or notions of international consistency reflecting po-
tentially conflicting principles. Implicit appeals to mea-
sure pure time preference also exist; however, this may
not be measurable if time and health are inextricably
linked. Furthermore, some health outcome measures may
already include individuals’ time preferences potentially
leading to double discounting. Implications will be dis-
cussed.
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AN ECONOMIC PROOF AND APPLICATION 
THAT FORMULARY RESTRICTIONS WITHIN 
DRUG CLASSES ALWAYS RESULT IN
HIGHER COSTS
Simons WR
Global Health Economics & Outcomes Research, Inc, Short 
Hills, NJ, USA
Pharmaceutical benefit providers use restrictive formular-
ies to control health care expenditures for drugs. One
type of restriction requires the use of one drug before the
use of another drug within the same drug. OBJECTIVE:
Test the hypothesis that restrictive formularies lower ex-
penditures for pharmaceuticals. METHOD: We use ex-
pected utility theory to derive equations for the restrictive
and unrestrictive formulary cases where the equations
take into account effectiveness (i.e., the probability of
attaining treatment goal and not attaining goal), alter-
natives if treatment fails and costs of each scenario. Ad-
ministrative costs are assumed zero. We prove mathe-
matically that restrictive formularies within drug classes
always cost more. Moreover, even if all drugs in the ther-
apeutic class are equal in effectiveness and equal in cost,
